Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 3,466 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intervention II Clear all
Not yet recruiting Phase 2 Interventional

SAMe in Prevention of Oxaliplatin-associated Liver Injury

NCT06258525
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Liver Injury, Sinusoidal Obstruction Syndrome, 5-Fluorouracil Toxicity, Liver Toxicity, Chemically-Induced
Interventions
Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery
Radiation · Dietary Supplement · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 4, 2026, 5:00 AM EST
Terminated Phase 2 Interventional Results available

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

NCT04720417
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Nov 4, 2026, 5:00 AM EST
Terminated Not applicable Interventional

A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection

NCT02005614
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Sarcoma, Breast Cancer, Lung Cancer, Colorectal Cancer, Gastrointestinal Cancers, Brain Metastases
Interventions
Gamma Knife Radiosurgery
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Nov 4, 2026, 5:00 AM EST
Completed Phase 2 Interventional

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

NCT05672355
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, COVID-19 Infection
Interventions
Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 4, 2026, 5:00 AM EST
Recruiting Phase 2 Interventional

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

NCT05998135
View directory record Official record
Conditions
Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma
Interventions
Atovaquone, Biopsy, Computed Tomography, Paracentesis
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 4, 2026, 5:00 AM EST
Recruiting Phase 1 Interventional

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

NCT07200089
View directory record Official record
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
NT-I7, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 4, 2026, 5:00 AM EST
Not yet recruiting Phase 2 Interventional

Folate Study in Men With Advanced Prostate Cancer

NCT06536374
View directory record Official record
Conditions
Prostate Cancer
Interventions
Trimethoprim Tablets
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 4, 2026, 5:00 AM EST
Recruiting Phase 1Phase 2 Interventional

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

NCT07456852
View directory record Official record
Conditions
Malignant Digestive System Neoplasm
Interventions
Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride, Electrocardiogram, Fluorouracil, Holter Monitoring, Isosorbide Mononitrate, Medical Device Usage and Evaluation, Placebo Administration, Questionnaire Administration
Procedure · Drug · Device + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 4, 2026, 5:00 AM EST
Completed Phase 2 Interventional

Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer

NCT00107484
View directory record Official record
Conditions
Breast Cancer
Interventions
ferumoxtran-10, magnetic resonance imaging, sentinel lymph node biopsy
Drug · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Nov 4, 2026, 5:00 AM EST
Recruiting Phase 2 Interventional

EUS-RFA PANCARDINAL-1 Trial

NCT04990609
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA), Neoadjuvant Chemotherapy (NAC)
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 4, 2026, 5:00 AM EST
Recruiting No phase listed Observational

A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors

NCT03432806
View directory record Official record
Conditions
Colon Cancer, Liver Tumors
Interventions
blood draws, colectomy or hepatectomy, Fibroscan test
Other · Procedure · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 4, 2026, 5:00 AM EST
Completed Phase 3 Interventional

INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant

NCT01602211
View directory record Official record
Conditions
Cancer Survivor, Depression, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome
Interventions
Internet-Based Intervention, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Tampa, Florida • Detroit, Michigan • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Nov 4, 2026, 5:00 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT01898793
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Fludarabine, Cyclophosphamide, Leukapheresis, Cytokine-induced killer cells, IL-2, ALT-803, Peripheral blood for correlative studies, Bone marrow for correlative studies
Drug · Procedure · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
2 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Nov 4, 2026, 5:00 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

NCT00556452
View directory record Official record
Conditions
Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant, Total Lymphoid Irradiation
Drug · Procedure · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Nov 4, 2026, 5:00 AM EST
Terminated Phase 3 Interventional Results available

Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT00513747
View directory record Official record
Conditions
Leukemia
Interventions
rituximab, fludarabine phosphate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
379
States / cities
Anniston, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 247 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Nov 4, 2026, 5:00 AM EST
Completed Phase 3 Interventional

Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II)

NCT00175058
View directory record Official record
Conditions
Myocardial Infarction
Interventions
AO Therapy (aqueous oxygen)
Device
Lead sponsor
TherOx
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Nov 4, 2026, 5:00 AM EST
Completed No phase listed Observational

Fast Assessment of STenosis Severity- FASTII Study

NCT03791320
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Vessel Fractional Flow Reserve
Diagnostic Test
Lead sponsor
Erasmus Medical Center
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Nov 4, 2026, 5:00 AM EST
Completed Phase 2 Interventional Results available

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

NCT02921256
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
Interventions
Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin, Oxaliplatin, Pembrolizumab, Veliparib
Drug · Radiation · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
645
States / cities
Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 449 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Nov 4, 2026, 5:00 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Parent and Family Obesity Intervention in Reducing Obesity Risk in Racial Ethnic Minority Families

NCT05094466
View directory record Official record
Conditions
Obesity-Related Malignant Neoplasm
Interventions
Behavioral Intervention, Counseling, Discussion, Educational Intervention, Informational Intervention, Interview
Behavioral · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 4, 2026, 5:00 AM EST
Terminated Phase 2 Interventional Results available

Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

NCT01009983
View directory record Official record
Conditions
Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
panitumumab, paclitaxel, carboplatin, laboratory biomarker analysis, immunohistochemistry staining method
Biological · Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
New Orleans, Louisiana • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Nov 4, 2026, 5:00 AM EST
Completed Phase 2 Interventional

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00073931
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, sargramostim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, tositumomab and iodine I 131 tositumomab
Biological · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
60 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Nov 4, 2026, 5:00 AM EST
Recruiting Phase 3 Interventional

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

NCT06724237
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2075
U.S. locations
164
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 4, 2026, 5:00 AM EST
Terminated Early Phase 1 Interventional

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

NCT04213794
View directory record Official record
Conditions
Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Gastric Carcinoma, Recurrent Liposarcoma, Recurrent Malignant Mesothelioma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Rectal Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Sarcoma, Refractory Colon Carcinoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Fallopian Tube Carcinoma, Refractory Gastric Carcinoma, Refractory Liposarcoma, Refractory Malignant Mesothelioma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Refractory Rectal Carcinoma, Refractory Rhabdomyosarcoma, Refractory Sarcoma, Resectable Liposarcoma, Resectable Malignant Mesothelioma, Resectable Sarcoma
Interventions
Cisplatin, Cytoreductive Surgery, Doxorubicin, Hyperthermic Intraperitoneal Chemotherapy, Sodium Thiosulfate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Nov 4, 2026, 5:00 AM EST
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors

NCT00002596
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions
bleomycin sulfate, filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older · Male only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
149
States / cities
Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 105 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Nov 4, 2026, 5:00 AM EST